OneSource Specialty Pharma Ltd management interview: Onesource Specialty Pharma Reports Strong Q2FY27 Performance | CNBC TV18
CNBC-TV18, 2026-10-29. Video: https://www.youtube.com/watch?v=6qAS-j0haYc
- September quarter: Revenue rose 37% year on year, margins expanded, and profit jumped multifold.
- Semaglutide supply: First supplies to Dr. Reddy’s for Canada and other markets are expected within this quarter. All 4 approvals are with OneSource customers, and Canada is expected to be a strong contributor in the second half.
- FY28 growth mix: Management expects semaglutide, biologics, injectables and softgel to contribute to the $400 million FY28 guidance; it did not quantify the split. The guidance is framed at around 28% margins.
- Biologics pipeline: Biologics is a high-margin business, but revenue in the guidance period is pre-commercialization R&D under MSAs. Commercialization is expected in ’29, ’30 and beyond, across biosimilars and new biologic entities.
- Capacity and China-plus-1: The new cartridge line is operational to serve existing demand and add customers; a third line is on site and expected to be available fully for FY28. China-plus-1 is contributing to RFP activity, with broader commercial benefits expected over the next 2 to 3 years.